Intermittent Fasting Improves Cardiometabolic Risk Factors and Alters Gut Microbiota in Metabolic Syndrome Patients
Guo Y, Luo S, Ye Y, Yin S, Fan J, Xia M
The Journal of clinical endocrinology and metabolism · 153 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Key Research and Development Program of China
- Government
- National Natural Science Foundation of China-Guangdong Joint Fund
- Grants
- National Natural Science Foundation of China-Guangdong Joint Fund (U1801281); National Key Research and Development Program of China (2017YFC0907101); National Key Research and Development Program of China (2017YFC0907100)
Based on 2 listed funder(s).
Publication
- Published
- 2020-10-05 · J Clin Endocrinol Metab · vol. 106 · issue 1 · pp. 64–79
- Publisher
- Oxford University Press
- Cited
- 196 citations · more than 99% of similar papers · 9.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 49 works
- Access
- Free to read
- Research areas
- Dietary Effects on Health · Gut microbiota and health · Diet and metabolism studies
- Keywords
- Metabolic syndrome, Gut flora, Medicine, Internal medicine, Physiology, Environmental health, Obesity, Immunology
- MeSH
- humans, cardiovascular diseases, treatment outcome, caloric restriction, fasting, body composition, adult, middle aged, china, female, male, obesity, abdominal, dysbiosis, gastrointestinal microbiome, metabolic syndrome, cardiometabolic risk factors
6 authors
From CN
- Yi GuoSun Yat-sen University
- Shiyun LuoSun Yat-sen University
- Yongxin YeSun Yat-sen University
- Songping YinSun Yat-sen University
- Jiahua FanSun Yat-sen University
- Min Xia · correspondingSun Yat-sen University
Abstract
Context
Intermittent fasting (IF) is an effective strategy to improve cardiometabolic health.
Objective
The objective of this work is to examine the effects of IF on cardiometabolic risk factors and the gut microbiota in patients with metabolic syndrome (MS).
Design and setting
A randomized clinical trial was conducted at a community health service center.
Patients
Participants included adults with MS, age 30 to 50 years.
Intervention
Intervention consisted of 8 weeks of "2-day" modified IF.
Main outcome measure
Cardiometabolic risk factors including body composition, oxidative stress, inflammatory cytokines, and endothelial function were assessed at baseline and at 8 weeks. The diversity, composition, and functional pathways of the gut microbiota, as well as circulating gut-derived metabolites, were measured.
Results
Thirty-nine patients with MS were included: 21 in the IF group and 18 in the control group. On fasting days, participants in the IF group reduced 69% of their calorie intake compared to nonfasting days. The 8-week IF significantly reduced fat mass, ameliorated oxidative stress, modulated inflammatory cytokines, and improved vasodilatory parameters. Furthermore, IF induced significant changes in gut microbiota communities, increased the production of short-chain fatty acids, and decreased the circulating levels of lipopolysaccharides. The gut microbiota alteration attributed to the IF was significantly associated with cardiovascular risk factors and resulted in distinct genetic shifts of carbohydrate metabolism in the gut community.
Conclusion
IF induces a significant alteration of the gut microbial community and functional pathways in a manner closely associated with the mitigation of cardiometabolic risk factors. The study provides potential mechanistic insights into the prevention of adverse outcomes associated with MS.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.